Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Nestlé S.A.    NESN   CH0038863350

NESTLÉ S.A.

(NESN)
  Report
Delayed Quote. Delayed Swiss Exchange - 11/27 11:30:25 am
102.3 CHF   -0.08%
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25NESTLE : Gets a Buy rating from JP Morgan
MD
11/25Nestle Agrees to Sell Yinlu Food Businesses in China
DJ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pandemic-Era Shoppers Splurge on Vitamins, Boosting Nestlé Sales -- Update

10/21/2020 | 06:34am EST

By Saabira Chaudhuri

Nestlé SA said the pandemic has increased consumers' health consciousness, boosting its small but fast-growing health-sciences unit and contributing to better-than-expected overall sales at the world's largest packaged-food maker.

The owner of Nescafe coffee, DiGiorno frozen pizza and Purina pet food has previously benefited from a pandemic-era shift by consumers to comfort food -- particularly big, trusted brands -- as they stocked up and stayed home during lockdowns.

As the pandemic wears on, companies are now getting a boost as consumers gravitate toward products that boost health, particularly the immune system.

Nestlé's health-science business has been one of its lesser-known divisions for years, but Chief Executive Mark Schneider, a former health-care executive who took the reins in 2017, has turned it into a focus area amid a wide-ranging portfolio shake-up. The unit represents only about 3% of Nestlé's overall sales, but Mr. Schneider said Wednesday he wanted it to become "a health and nutrition powerhouse" through acquisitions and organic growth.

Nestlé said the unit delivered double-digit sales growth in the first nine months of the year, but didn't detail its performance any further in a sales update released Wednesday.

Demand for vitamins, minerals and supplements was strong, the company said. Supplement brands Garden of Life and Pure Encapsulations sold particularly well online. So called healthy-aging products grew at a double-digit rate in the nine-month period, Nestlé said, with help from Boost, a nutritional drink brand, in North America and Nutren, a line of nutritional supplements, in Brazil.

Health-science sales lifted overall revenue, which was powered by strong pet food and coffee sales. Nestlé said organic sales, which strip out currency fluctuations, acquisitions and divestitures, grew 3.5% in the first nine months of the year, beating analysts' estimates of 2.8%. Results were driven almost entirely by volume growth. The company upgraded its guidance for the year, saying it now expects organic sales growth of around 3%, from a prior forecast of between 2% and 3%.

Nestlé shares were largely unchanged in late morning trading in Europe.

Net sales fell 9.4%, to 61.91 billion Swiss francs, equivalent to $68.24 billion, dragged down by currency changes and divestitures. Mr. Schneider has sold a string of assets, including Nestlé's skin-health arm and U.S. ice-cream business, as he pivots toward categories he sees as higher growth.

Other companies have reported sales boosts amid a shift in health consciousness by consumers.

Conagra Brands Inc. says its Healthy Choice frozen meals are on the rise. Reckitt Benckiser Group PLC this week said its Airborne brand, a supplement advertised as boosting the immune system, more than doubled revenue in the third quarter.

Others have moved to take advantage of the increased concern about health during the pandemic. Unilever PLC has doubled the amount of zinc that goes in its Horlicks brand, a malted milk bestseller in India, and is marketing what it says are the brand's immunity-boosting benefits.

Nestlé has a head start, having set up the health-science business in 2011 under former CEO Paul Bulcke, now the company's chairman. His vision was to use specialist food-based products to help prevent and treat conditions such as Alzheimer's disease, diabetes and heart disease. Nestle has also been investing in treatments and medicine.

It has made a long string of acquisitions to bolster the unit, earlier this month closing a deal to buy a California-based biopharmaceutical company that has won approval for the first treatment for peanut allergies. The acquisition valued Aimmune Therapeutics Inc. at $2.6 billion, including debt, and analysts expect Nestle to keep doing big deals.

This year, Nestlé bought a gastrointestinal medication brand and took a majority stake in a company that makes collagen supplements.

Still, for all the focus on it, the health-science arm remains far smaller than older units such as coffee and petcare, which remained the main drivers of Nestlé's strong sales for the period. Pet food, where sales rose 4.1% in the nine months, has performed well for years.

The company said its dairy and cooking-aids arms also did well. Confectionery and bottled water dragged down the results, with both categories heavily dependent on tourism and shoppers being out and about.

After lifting lockdowns, many countries -- particularly in Europe -- are now implementing strict bans on movement again to stem the spread of the virus. Nestle said the out-of-home sales channel overall "remained significantly negative," but sales declines moderated in the third quarter.

Write to Saabira Chaudhuri at saabira.chaudhuri@wsj.com

(END) Dow Jones Newswires

10-21-20 0633ET

Stocks mentioned in the article
ChangeLast1st jan.
NESTLÉ S.A. -0.08% 102.3 Delayed Quote.-2.37%
All news about NESTLÉ S.A.
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25NESTLE : Gets a Buy rating from JP Morgan
MD
11/25Nestle Agrees to Sell Yinlu Food Businesses in China
DJ
11/25NESTLE S A : sells Yinlu business in China amid portfolio cleanup
RE
11/25NESTLE S A : sells Yinlu business in China amid portfolio cleanup
RE
11/25NESTLE S A : Nestlé agrees to sell Yinlu peanut milk and canned rice porridge bu..
AQ
11/23Danone to cut jobs, product lines in virus-led restructuring
RE
11/12Nestle Appoints New Head of Strategic Business Units, Marketing and Sales
DJ
11/12NESTLE S A : Changes in the Executive Board of Nestlé S.A.
PU
11/12NESTLE S A : Changes in the Executive Board of Nestlé S.A.
AQ
More news
Financials
Sales 2020 84 945 M 93 839 M 93 839 M
Net income 2020 11 697 M 12 921 M 12 921 M
Net Debt 2020 30 184 M 33 344 M 33 344 M
P/E ratio 2020 25,2x
Yield 2020 2,66%
Capitalization 285 B 315 B 315 B
EV / Sales 2020 3,71x
EV / Sales 2021 3,68x
Nbr of Employees 291 000
Free-Float 93,5%
Chart NESTLÉ S.A.
Duration : Period :
Nestlé S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NESTLÉ S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 117,02 CHF
Last Close Price 102,30 CHF
Spread / Highest target 27,1%
Spread / Average Target 14,4%
Spread / Lowest Target -8,11%
EPS Revisions
Managers
NameTitle
Ulf Mark Schneider Chief Executive Officer & Director
Paul Bulcke Chairman
Magdi Batato Executive Vice President-Operations
François-Xavier Michel Marie Roger Chief Financial Officer & Executive Vice President
Stefan Palzer Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
NESTLÉ S.A.-2.37%314 978
DANONE S.A-28.58%40 978
THE KRAFT HEINZ COMPANY2.21%40 151
MCCORMICK & COMPANY9.34%24 863
WILMAR INTERNATIONAL LIMITED4.85%20 316
BEYOND MEAT, INC.88.10%8 910